Editorial Policy

How we ensure accuracy, transparency, and trustworthiness in our ibogaine treatment content.

Our Mission

Ibogaine Treatment Guide exists to provide independent, evidence-based information about ibogaine therapy for addiction, mental health conditions, and neurological disorders. We are committed to helping individuals make informed decisions by presenting the best available scientific evidence alongside practical treatment guidance.

Content Standards

  • Evidence-based: All medical claims are supported by peer-reviewed research, clinical trial data, or established medical consensus. We cite PubMed-indexed studies (PMIDs) wherever possible.
  • Balanced: We present both potential benefits and risks of ibogaine treatment. Safety warnings and contraindications are prominently displayed on every treatment page.
  • Current: Content is reviewed and updated regularly to reflect the latest research, clinical trial results, and regulatory developments.
  • Transparent: We clearly distinguish between established evidence, emerging research, and anecdotal reports. When evidence is limited, we say so.

Medical Review Process

Our content undergoes a multi-step review process:

  1. Research and drafting: Content is researched using PubMed, Google Scholar, ClinicalTrials.gov, and other peer-reviewed sources. Each article cites specific studies with PMID references.
  2. Clinical accuracy review: Medical content is reviewed for accuracy by our editorial team, which includes individuals with clinical research backgrounds and expertise in psychedelic-assisted therapy.
  3. Fact-checking: Statistics, dosage information, contraindications, and drug interactions are verified against published literature before publication.
  4. Ongoing updates: Published content is periodically reviewed and updated when new research becomes available or when existing data is superseded.

Sources We Rely On

  • PubMed-indexed peer-reviewed journals (e.g., Psychopharmacology, Journal of Psychedelic Studies, American Journal of Drug and Alcohol Abuse)
  • ClinicalTrials.gov registered studies (NCT numbers cited)
  • Institutional research from Stanford, Johns Hopkins, MAPS, and the Global Ibogaine Therapy Alliance
  • Published case reports and observational studies from licensed treatment facilities
  • FDA and DEA regulatory documents

Advertising and Sponsorship Disclosure

This guide is operated independently. When we mention specific treatment providers, we clearly distinguish editorial content from provider information. Our editorial decisions are not influenced by commercial relationships. We may link to treatment providers as informational resources, but provider mentions do not constitute endorsement or medical advice.

Important Disclaimers

This guide is not medical advice. Ibogaine treatment carries significant risks, including cardiac complications and potentially fatal drug interactions. Always consult with qualified medical professionals before considering ibogaine therapy.

Ibogaine is classified as a Schedule I substance in the United States and is illegal in several other countries. Its legal status varies by jurisdiction.

If you or someone you know is in crisis, contact the SAMHSA National Helpline at 1-800-662-4357 (free, confidential, 24/7) or text HOME to 741741 for the Crisis Text Line.

Contact Our Editorial Team

If you believe any content on this site contains an error, or if you have suggestions for improvement, please contact us. We take accuracy seriously and will investigate and correct verified errors promptly.

Last updated: March 2026